Form 4: Adaptimmune Therapeutics PLC: Chief Commercial Officer Reports Option Grants

Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics PLC, reports the acquisition of options to purchase ordinary shares.

Summary

• Cintia Piccina, the Chief Commercial Officer of Adaptimmune Therapeutics PLC, filed a Form 4 on February 20, 2025.
• The filing reports the acquisition of options to purchase 1,612,032 ordinary shares at an exercise price of $0.1 and 1,074,696 ordinary shares at an exercise price of $0.0013.
• The options were granted on February 20, 2025.
• The first set of options (1,612,032 shares) vests in installments starting February 20, 2026.
• The second set of options (1,074,696 shares) vests in annual installments starting February 20, 2026.

Sentiment

Score: 7

Explanation: The document itself is neutral, reporting a standard executive compensation event. The sentiment is slightly positive as it indicates continued investment in key personnel.

Positives

• The grant of options to a key executive aligns their interests with those of the shareholders.

Industry Context

Option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including option grants, are typically benchmarked against peer companies in the biotechnology sector.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar equity-based compensation strategies to incentivize key personnel.
• The vesting schedules and exercise prices are generally structured to reward long-term performance and retention.

Key Dates

Keywords

Adaptimmune Therapeutics, Form 4, Cintia Piccina, Chief Commercial Officer, Option grant, Ordinary shares, Beneficial ownership